Evaluating online sourcing channels for CJC-1295 DAC requires strict verification of compound purity, sequence integrity, and analytical transparency. PX1 Research provides laboratories worldwide with USA-manufactured CJC-1295 DAC backed by lot-specific certificates of analysis, RP-HPLC testing, and mass spectrometry validation for specialized in vitro and preclinical research applications.
Evaluating online sourcing channels for CJC-1295 DAC requires strict verification of compound purity, sequence integrity, and analytical transparency. PX1 Research provides laboratories worldwide with USA-manufactured CJC-1295 DAC backed by lot-specific certificates of analysis, RP-HPLC testing, and mass spectrometry validation for specialized in vitro and preclinical research applications.
When evaluating CJC-1295 DAC vendita online, research institutions must select qualified chemical suppliers that supply high-purity, USA-manufactured peptides for laboratory research use only. CJC-1295 DAC is a synthetic growth-hormone-releasing hormone (GHRH) analog engineered with a Drug Affinity Complex to extend systemic half-life, requiring lot-specific RP-HPLC, mass spectrometry, and endotoxin verification before experimental deployment.
Navigating the global market for research peptides presents significant quality control challenges. Chemical purity can vary widely depending on the synthesizer's purification protocols, solid-phase peptide synthesis (SPPS) parameters, and post-synthetic processing. Researchers seeking to procure our CJC-1295 DAC product page must ensure that the vendor provides transparent, batch-specific analytical documentation to prevent experimental confounding caused by sequence truncation, residual trifluoroacetic acid (TFA), or heavy metal contaminants.
PX1 Research operates dedicated manufacturing and distribution operations out of California and Arizona, providing same-day dispatch Monday through Friday for validated academic, commercial, and institutional laboratories. By enforcing ISO 17025 testing standards across our entire catalog, PX1 Research delivers fully characterized reference materials designed strictly for in vitro assays and preclinical animal models.
CJC-1295 DAC is a modified 29-amino acid tetrasubstituted peptide derivative of endogenous Growth Hormone Releasing Hormone (GHRH 1-29). The molecule incorporates D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These amino acid substitutions significantly enhance resistance to enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV), an enzyme that rapidly inactivates native GHRH in biological matrices.
The key structural innovation in CJC-1295 DAC is the bioconjugation of a Drug Affinity Complex (DAC) linker—specifically maleimidopropionic acid—to the lysine residue at the C-terminus. In preclinical plasma models, this reactive maleimide moiety forms a stable, covalent thioether bond with circulating serum albumin at the Cys-34 residue. Because serum albumin possesses an extended systemic half-life, the resulting peptide-protein complex exhibits a dramatically reduced renal clearance rate and prolonged biological activity.
Mechanistically, CJC-1295 DAC acts as a potent agonist at the growth hormone-releasing hormone receptor (GHRH-R) located on anterior pituitary somatotrophs. Upon receptor binding, it activates the G-protein-coupled adenylate cyclase pathway, increasing intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA). This cascade signals the transcription and exocytosis of growth hormone (GH), which subsequently stimulates hepatic synthesis of insulin-like growth factor 1 (IGF-1).
In vitro and animal models evaluating CJC-1295 DAC demonstrate a unique pharmacokinetic profile compared to short-acting GHRH secretagogues. Preclinical investigations in rodent models reveal that a single administration of CJC-1295 DAC leads to sustained elevations in circulating growth hormone and downstream IGF-1 levels for several days. This extended duration of action is directly attributable to the albumin-binding mechanism provided by the DAC moiety.
Researchers investigating tissue repair, cellular regeneration, and metabolic pathways utilize CJC-1295 DAC to examine continuous GHRH receptor stimulation without requiring continuous micro-infusion equipment. Preclinical studies suggest that elevated systemic IGF-1 levels secondary to CJC-1295 DAC exposure promote collagen deposition, accelerate myoblast proliferation, and influence lipid substrate oxidation in laboratory models.
Importantly, preclinical data indicate that despite extended receptor engagement, CJC-1295 DAC preserves the slow, wave-like secretion patterns of pituitary GH, although baseline inter-pulse growth hormone concentrations remain elevated. Comparative data held in our comprehensive research peptide database illustrate how continuous GHRH signal transduction impacts receptor downstream sensitivity, desensitization kinetics, and somatostatin feedback mechanisms in experimental settings.
When designing preclinical protocols focusing on the somatotropic axis, investigators frequently compare CJC-1295 DAC with alternative GHRH analogs and growth hormone secretagogues. The primary functional distinction lies in half-life, receptor binding duration, and pulsatility modulation. Understanding these differences allows research teams to select the appropriate compound for their specific experimental endpoints.
For instance, evaluating CJC-1295 without DAC (also known as Modified GRF 1-29) reveals a short elimination half-life of approximately 30 minutes in animal models. This rapid clearance mirrors natural physiological GHRH pulses, making it ideal for studies examining discrete, transient GH release. Conversely, CJC-1295 DAC provides extended receptor occupation over days, establishing persistent basal IGF-1 upregulation.
Furthermore, investigators often combine or contrast GHRH analogs with selective ghrelin receptor agonists. Integrating ipamorelin research or evaluating GHRP-6 analytical profiles alongside GHRH agonists demonstrates a synergistic amplification of GH release in vitro. While GHRH analogs activate the cAMP/PKA signaling pathway via GHRH-R, ghrelin mimetics stimulate the growth hormone secretagogue receptor (GHS-R1a) via the phospholipase C (PLC)/IP3 pathway. Studying these distinct pathways side-by-side provides critical insight into dual-receptor regulation of somatotroph exocytosis. For broader exploration of these classes, researchers can review our complete GHRH analog library.
Purchasing CJC-1295 DAC online for institutional laboratory use requires stringent vendor evaluation. Peptides synthesized without rigorous process controls often contain synthesis truncations, deletion sequences, unreacted coupling reagents, or excessive TFA salts. These impurities compromise assay reproducibility and can cause off-target cytotoxicity in cell culture models.
At PX1 Research, every single lot of CJC-1295 DAC undergoes independent verification by accredited ISO 17025 analytical laboratories. Sourcing verification relies on two primary analytical techniques:
1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Determines chemical purity by separating the primary peptide peak from synthesis byproducts, diastereomers, and degradation impurities. PX1 Research mandates a minimum purity threshold of 98.0% for all research peptides. 2. Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms exact molecular weight and amino acid sequence identity, verifying that the maleimide DAC complex is intact and attached at the correct C-terminal position.
Laboratories can review batch-specific Certificates of Analysis (COAs) directly on our platform prior to purchase, ensuring full analytical traceability from synthesis to experimental application.
Endotoxin contamination is a primary cause of non-specific inflammatory signaling and cell toxicity in cell culture and animal tissue models. Bacterial lipopolysaccharides (LPS) introduce profound background noise in gene expression profiling, cytokine assays, and histological tissue repair studies.
PX1 Research integrates rigorous Limulus Amebocyte Lysate (LAL) testing protocols for all synthesized peptide lots. Our strict quality thresholds ensure that endotoxin levels remain below stringent research limits (<0.01 EU/mg), preserving cellular viability and preventing artifactual activation of Toll-like receptor 4 (TLR4) pathways during in vitro research.
Additionally, every unit dispatched from our USA facilities features full lot traceability. Digital tracking numbers link each vial directly to its corresponding raw material synthesis logs, purification chromatographic profiles, and mass spectral data, guaranteeing unmatched accountability for institutional compliance.
To maintain the structural integrity of CJC-1295 DAC during laboratory storage and reconstitution, research personnel must follow standard biochemical handling procedures. Lyophilized peptide powder is sensitive to moisture absorption, room temperature thermal degradation, and mechanical shear forces.
Lyophilized CJC-1295 DAC should be stored in desiccated sealed containers at -20°C for short-term projects or -80°C for extended archival storage. Prior to reconstitution, vials should be allowed to equilibrate to ambient laboratory room temperature to prevent condensation formation inside the container.
Reconstitution should be performed using laboratory-grade sterile bacteriostatic water or sterile standard saline, depending on the requirements of the downstream assay. Solvent should be added gently down the side of the glass vial, followed by gentle swirling. Severe agitation or vortexing must be avoided, as physical shear stress can denature the tertiary structure or cause aggregation. Reconstituted aliquots should be used immediately or stored at -80°C to prevent freeze-thaw degradation cycles.
The supply chain for research chemicals frequently suffers from inconsistent quality, unverified overseas drop-shipping, and missing batch documentation. Laboratories sourcing CJC-1295 DAC online must prioritize suppliers operating within fully compliant domestic frameworks.
PX1 Research manufactures and packages all peptides within modern, cGMP-compliant facilities located in the United States. Operating out of dual fulfillment hubs in California and Arizona allows us to maintain strict cold-chain logistics, eliminate international customs clearance delays, and guarantee rapid order processing.
By utilizing third-party testing from accredited ISO 17025 testing laboratories, PX1 Research eliminates conflicts of interest in chemical reporting. Principal investigators receive raw HPLC chromatograms and mass spectra rather than stylized or unverified batch summary sheets, ensuring total data integrity for scientific publication.
PX1 Research supports university research departments, pharmaceutical discovery laboratories, and contract research organizations (CROs) requiring ongoing bulk supplies of research peptides. We accommodate bulk order requests, custom synthesis parameters, and multi-lot stability testing protocols.
Institutional buyers can establish a dedicated wholesale laboratory account to access volume-based pricing structures, standardized procurement billing, and reserved single-lot inventory allocations to guarantee consistent batch controls across longitudinal studies.
To review our complete catalog of purified GHRH analogs, secretagogues, and tissue repair peptides, researchers are encouraged to browse our complete research catalog or contact our technical support team for detailed certificate requests.
What is the primary difference between CJC-1295 DAC and CJC-1295 No DAC?
The primary difference lies in the presence of the Drug Affinity Complex (DAC). CJC-1295 DAC binds covalently to circulating serum albumin, extending its biological half-life to several days in animal models. CJC-1295 No DAC (Modified GRF 1-29) lacks this complex and exhibits a rapid clearance half-life of approximately 30 minutes.
How does PX1 Research verify the purity of CJC-1295 DAC?
Every lot of CJC-1295 DAC undergoes reverse-phase high-performance liquid chromatography (RP-HPLC) to verify chemical purity (≥98%) and electrospray ionization mass spectrometry (ESI-MS) to confirm sequence mass identity. COAs are publicly accessible for every batch.
What are the recommended laboratory storage conditions for CJC-1295 DAC?
Lyophilized CJC-1295 DAC powder should be stored desiccated at -20°C or -80°C. Reconstituted peptide solutions should be stored in small aliquots at -80°C to minimize degradation and avoid repeated freeze-thaw cycles.
Is CJC-1295 DAC approved for human consumption or therapeutic use?
No. CJC-1295 DAC supplied by PX1 Research is strictly sold as a research chemical for laboratory, in vitro, and preclinical animal research use only. It is not for human or veterinary diagnostic, therapeutic, or clinical applications.
What is the endotoxin limit for CJC-1295 DAC from PX1 Research?
PX1 Research conducts LAL endotoxin testing on all research peptides to ensure endotoxin levels remain below strict laboratory limits (<0.01 EU/mg), preventing non-specific inflammatory reactions in cell culture and animal tissue models.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are synthesized in USA-based, cGMP-compliant facilities and shipped directly from our primary fulfillment hubs in California and Arizona with same-day dispatch available M–F.
Can academic institutions set up wholesale or bulk purchasing accounts?
Yes. Qualified academic, institutional, and private research laboratories can set up a wholesale account to receive volume pricing, batch reservation, and custom lot testing documentation.
Which solvents are recommended for reconstituting CJC-1295 DAC in vitro?
Standard reconstitution for laboratory assays utilizes sterile bacteriostatic water or sterile 0.9% sodium chloride solution. Gentle swirling is advised to prevent structural shear stress.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.